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ABSTRACT An enormous amount of drug supply is regularly wasted due to several reasons related to
incorrect prescription, purchase of unnecessary quantities, drug intolerance, allergy, or interactions. On the
other hand, these medicines may be needed by patients who cannot afford to purchase them. To address
this challenge, we propose a fully decentralized solution that governs the return and redistribution of unused
drugs that are fit for usage. Our approach exploits the decentralized blockchain technology, smart contracts,
and decentralized storage systems such as the Interplanetary File Systems (IPFS). We develop a system that
provides the ability for customers as well as pharmacies to return re-usable, resellable drugs for donation or
resale at a lower price. The proposed scheme tracks the production of drugs frommanufacturers to traders that
subsequently sell them to customers. Unused drugs can be returned after approval by specialized entities and
then redistributed. In particular, we present the decentralized system architecture and implement a prototype
on a test Ethereum blockchain platform to present the suggested workflow. Further, we provide system
evaluation focused on assessing system functionality, performance, execution cost, and security of smart
contracts and their robustness. We have also made our smart contracts code publicly available on Github. 1.
INDEX TERMS Blockchain, ethereum, healthcare, returned drugs, trustworthy tracking.
I. INTRODUCTION
Tracking drugs is a vital feature to ensure the trusted and safe
delivery of medicine in-line with acceptable conditions. The
life cycle of a typical medicine starts with the manufacturers
that produce lots or batches of drugs. These lots are then pro-
cessed through multiple entities ending with traders that sell
these drugs to customers. This supply chain undergoes several
changes of ownership until drugs are sold to a customer, with
the process being recorded to track the medicine from its
origin until it has been sold. However, the prescribed drugs
may not be consumed due to several reasons such as change
of dosage advised by the doctor, change in the course of
treatment, or allergic reactions, etc. leading to drugs that are
no longer needed by the patient. Ideally, these drugs should
be passed along to other patients that would benefit from
them. However, this process is not easy to manage as these
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drugs need to be examined by appropriate authorities and
proven to be fit for further use before being made available
for redistribution. The redistribution of unused, safe medicine
for a lower price or for free can save the lives of many patients
who cannot afford medication, especially in countries where
such drugs are expensive [1]. Moreover, this process can save
millions of dollars annually in medicine that otherwise would
have just gone to waste as well as a positive impact on the
environment as most unused medicines are often disposed of
in garbage cans or water bodies.
A system for tracking unused drugs and validating their
condition typically requires a centralized server to trace each
medicine as it is transferred between different stakehold-
ers. These stakeholders include manufacturers, distributors
(pharmacies and hospitals), and customers. Although this
central authority tracks the medicine journey, it suffers from
major drawbacks. For instance, there are security and privacy
concerns regarding centralized systems as they are always
susceptible to being attacked and compromised. A decen-
tralized approach, such as using the blockchain technology,
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eliminates the dependency on a central server to track the
delivery of medicine. A blockchain is a decentralized ledger
that records transactions in a tamper-proof manner. Some
blockchain networks employ a smart contract, which is a
piece of code deployed on the blockchain used to implement
arbitrary logic customized by the user. Smart contracts can
be used to trace the drug from manufacturing to sale and to
record the return of drug packages, approve and re-sell them
to new customers.
A conventional drug supply chain can track medicines
throughout its journey, i.e., from the manufacturer to the
distributor and from the distributor to a pharmacy or a hospi-
tal/medical center. However, employing blockchain extends
this functionality to expand the chain of custody to include
the consumers of this medicine, where it can record the
purchase of any medicine along with the customer and pre-
scription details. By doing so, blockchain can also provide
patients the ability to re-sell or donate unused medicine
back to the distributor. This approach provides an immutable
history for the medicine from dispatching the original lot
by the manufacturer until a seller collects it. Furthermore,
the blockchain ledger holds records that show when a drug
package was returned, approved, and re-sold while ensuring
that all returned packages are sealed, tamper-proof, and safe
to use condition. The major contributions of this article are:
• We propose a decentralized system leveraging the
blockchain technology to facilitate the safe and secure
return and redistribution of unused drugs. The solution
engages all relevant entities to ensure that the process
of retaking, approving, and re-selling drugs is safe and
certified by authorized members.
• Utilizing blockchain capabilities, we present an auto-
mated method to choose a reseller through an auctioning
mechanism. In addition, we provide a way for patients
to give feedback about the resellers based on their per-
formance.
• We provide implementation details for the system func-
tionality on the Ethereum blockchain. We present the
sequence of interactions for purchasing, returning, and
resale of the unused drugs as well as selecting and evalu-
ating resellers. This implementation is achieved through
a virtual blockchain platform using Remix IDE.
• We present detailed system evaluation focused on
assessing system functionality, performance, execution
cost, and security of smart contracts and their robustness.
Different scenarios were investigated and presented to
assess the feasibility of the solution. We also compare
our approach to existing solutions and highlight chal-
lenges that remain for the effective adoption of the pro-
posed solution in wider domains.
The remainder of the article is organized as follows:
Section II explains the concept of blockchain and smart con-
tracts. Section III presents a critical overview of the related
work. Section IV presents the proposed approach for the
returning and resale of unused drugs. Section V explains
the implementation details followed by section VI which
demonstrates the smart contract testing results. Section VII
presents an analysis and evaluation of the proposed approach.
Section VIII concludes the article.
II. BLOCKCHAIN BACKGROUND
Blockchain is a distributed ledger technology that gained
popularity from one of the most common cryptocurrencies,
the Bitcoin [2]. The blockchain can be viewed as a system
of interconnected peers that share the same state machines.
Members of the blockchain network transact information
between each other, and these transactions are grouped
together to form a structure called a block. Each block
consists of numerous transactions that are assembled and
appended to the existing list of blocks by blockchain miners.
Blocks are mined and agreed upon among the blockchain net-
work participants following a consensus protocol. A variety
of consensus protocols have been proposed to determine the
behavior of the blockchain network [3]. Various consensus
protocols follow different approaches to reach an agreement
on which miner validates and aggregates transactions into a
block that is then acknowledged by other members of the
network. This block is broadcasted to the entire peer-to-peer
network and replicated at all nodes to store a common public
state of the blockchain.
A blockchain can be public or private, depending upon
the use-case involved. Both private and public blockchains
have been gaining a lot of popularity due to their infi-
nite applications. Extensive research has been conducted to
study the application of blockchain in the fields of IoT,
AI, Supply Chain, and Fog Computing, as it can be seen
in these articles. [4]–[7]. The pharmaceutical supply chain,
in specific, is one of the most suitable applications for
blockchain. Introducing a distributed ledger to handle track-
ing drugs has several beneficial advantages [8]. By nature,
blockchain is an immutable record of transactions, and
hence, all interactions captured are permanent, persistent,
and tamper-proof. Hence, the drug delivery process that
utilizes the blockchain technology will be secure, and the
quality of service provided to patients is required to meet
a certain standard. Blockchain can restrict access of infor-
mation to certain members of the network (through permis-
sioned blockchain model), which ensures the integrity of
data.
Some blockchain networks deploy smart contracts to
implement customizable business logic. Smart contracts are
passive elements used in blockchains such as Ethereum and
Hyperledger to achieve numerous functionalities. For easier
usage of the blockchain, smart contracts are often deployed
as back-end systems that communicate with decentralized
applications (DApps) at the front-end. DApps offer a usable
interface for users to interact with the blockchain layer. In the
case of the drug supply chain, DApps can be used to transfer
data about drug lots between different entities, sell drugs
to patients, and return unused drugs via a simple logical
interface.
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FIGURE 1. Proposed decentralized architecture for tracking returned drugs.
III. RELATED WORK
This section presents a critical overview of existing work
done on drug delivery and tracking solutions. Most of these
solutions utilize a central server to manage drug lots and
re-usable packages. The blockchain technology is not used
extensively in any of the mechanisms that enable patients to
return unused drugs for redistribution.
The tracking of medicine from manufacturers to distrib-
utors is often achieved through well-established methods
and tracking systems. Research in the food and drug supply
chain industry has been an area of continuous development,
as evident in some of the early research articles such as [9]
that presented the traceability in the Agri-food Supply Chain
and [10] that discussed how to streamline the supply chain
in pharmaceutics. The latter presented clear shortcomings in
the conventional decision-making process. These problems
are consequences of a large number of stakeholders and the
large inventory available and result in significantly inflating
the process cycle time. Some solutions, such as introducing
continuous processing, has been proposed to shorten this
cycle time [11]. Nonetheless, the concept of centralization
acts as a bottleneck in such a system.
Since the emergence of the blockchain technology, notable
efforts have been made to exploit it to achieve drug tracking
as an alternative to the current systems. The authors in [12]
present a blockchain-based solution called Drugledger. Their
model achieves the privacy and authenticity of data by break-
ing down the service providers into separate entities. Another
solution presented a blockchain-based supply chain to
establish trusted medical records for drugs and patients [13].
These records can be accessed for a limited time only.
Trace and Track is another model developed to store
records of medicine [14]. It combines an IoT framework
with blockchain to introduce trust into a trust-less inter-
action between stakeholders and fight counterfeit drugs.
Some real-life applications have also been developed to
deploy the blockchain for pharma supply chain manage-
ment. Good Shepherd pharmacy in the US and its sister
company RemediChain developed a blockchain platform
that manages the donation of unused drugs [15]. Another
solution that utilizes blockchain for the medical supply
chain is modum.io [16], which uses the blockchain along
with IoT devices to store medicine records efficiently and
securely.
The majority of the existing traditional solutions use a cen-
tralized server to manage the pharmaceutical supply chain.
In contrast, we are proposing to use a decentralized approach
to eliminate the need for a centralized entity, thereby main-
taining data integrity, privacy, and security. Several other
presented solutions utilize the blockchain technology but
target different aspects of the medicine supply chain. These
applications offer mechanisms for drug traceability, detecting
counterfeit drugs, preventing fraud, and other applications.
However, none of this work proposes a way to return unused
drugs, validate them, and sell them to patients. On the other
hand, one of the main contributions of our solution is sug-
gesting a mechanism to accept returned drugs by certified
agencies that offer them for resale. Undoubtedly, this is
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implemented in a decentralized manner on the blockchain via
Ethereum smart contracts.
IV. PROPOSED APPROACH
Fig. 1 presents a high-level architecture for our proposed
system that tracks the journey of medication from its ori-
gin to the purchase by consumers. This supply chain has
attracted attention from existing work; however, our proposed
architecture connects all stakeholders via the blockchain net-
work that cryptographically records all transactions. Several
blockchain networks can be utilized for the use-case of this
approach. These include the Ethereum network, both private
and public, Hyperledger Fabric, and Multichain. While some
parts of the supply chain can be implemented to be private,
most of the smart contract data need to be available publicly.
The blockchain network chosen in our solution is the public
Ethereum blockchain. Ethereum is a public blockchain that
supports smart contracts written in Solidity language. This
network is suitable as the data should be publicly available
for all members to check and verify. Nevertheless, each entity
has specific privileges and is given the authority to a specified
set of methods that it can invoke. For example, the Food and
Drug Administration (FDA) is considered the highest level
of authority and can access all information in the system.
Each of these members is identified in the blockchain to other
nodes by a 20-byte Ethereum Address that is linked to all of
its relevant data.
The tracking of drugs begins when a manufacturer pre-
pares drugs and medications according to orders received
from hospitals, pharmacies, or any drug distributor. After
manufacturing the drug lot or batch and performing testing
on the generated drugs, the manufacturer updates a summary
smart contract of the drug batch. This contract holds all
the information about approved drugs, manufacturers, and
sellers. The manufacturer also uploads an image of the lot to
a decentralized storage system such as the InterPlanetary File
System (IPFS). The drug is identified in the summary contract
by a drug code. The lot is approved if the manufactured drug
is registered and validated according to the summary contract.
After the drug lot has been approved, a new smart contract
is created for that lot. The smart contract is identified by
a unique address and contains information about the drug,
including its name, date of expiration, price, and the number
of boxes in the lot. The required quantity from the lot is
shipped to the retailer and then sold to patients individually.
Whenever a sale takes place, the seller updates the smart
contract by providing the box number that was sold. This is
done to help verify the source of the box if this box is returned.
With the sale of a drug box, the blockchain no longer tracks
the movement of the drug box.
If a customer wishes to return the medicine at a lower price
or donate it, the customer returns the medicine to a certifi-
cation agency that manages redistribution. In addition, both
manufacturers and drug sellers can provide these drugs for
resale. These agencies that receive returned or donated drugs
are certified by the government to approve drugs eligible
for resale. The certification agency verifies the suitability
of the drugs for resale, which includes various assessments
including confirmation of the shelf life of the medicine, veri-
fying that the packaging is still sealed, and that it was stored
in appropriate conditions including temperature, luminosity,
and humidity etc. Satisfactory completion of these assess-
ments means that the medicine is considered fit for usage.
In addition to certifying drugs, the certification agency cre-
ates a new smart contract for the returned package containing
relevant data referring to the origin of the drug as well as
new data. Furthermore, the certification agency updates the
returned drug summary smart contract with the new address
of the returned package. The certification agency also uploads
a new image of the repackaged drug to the decentralized
storage system.
The selection of a drug reseller to receive the drug package
is made through an auctioning mechanism. A reseller offers
the returned drugs at a lower price or donates them depending
on the previous owner’s request. Patients can then review
these drugs and can purchase them at lower prices or for free.
The certification agency starts an auction with its preferred
parameters, including the starting price and the closing time
for the auction. Approved resellers can place bids in this
auction to get the returned package. In order to distinguish
good resellers, each one is given a reputation score. A certi-
fication agency can enforce a minimum reputation score for
auctions to ensure the desired quality of service. After the
transaction with the patient, the patient provides its feedback
to the reputation smart contract, which updates the reputation
score of the reseller.
As blockchain is an immutable ledger, certification agen-
cies, as well as customers, can trace the history of each drug
and the change of ownership throughout its life cycle. This
can be achieved by exploring transactions and events to and
from the smart contract, which are permanently stored on
the blockchain. For instance, if at any point in the life cycle
of the medicine, a medication is discovered to be spoiled
or damaged, the last entity to approve the quality of the
products is to be held responsible. Therefore, all members are
forced to perform appropriate tests on the goods to avoid any
repercussions, either financially or the credibility of the entity
among the members of the network. Moreover, all certifica-
tion agencies and drug resellers are envisaged to be certified
to ensure trust in the process of returned drug validation.
The pharmaceutical supply chain consists of several stake-
holders, where primary elements are elaborated below.
• FDA:Tomonitor drug suppliers, pharmacies and health-
care centers, and any entity involved in the process
of producing and selling drugs, a central authority is
essential. The FDA is a federal agency in the United
States responsible for maintaining public health by
monitoring and controlling the production of foods
and pharmaceutical drugs. The FDA authorizes drug
prices, sales, as well as certification agencies, and drug
resellers. Furthermore, it has privileged access to all
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FIGURE 2. Smart contract structure design.
methods and data in the smart contract, which all other
entities may not have.
• Manufacturers: Manufacturers initiate the supply
chain and produce drugs in lots in order to ship them to
retailers. Manufacturers create a smart contract for each
new lot and provide the summary smart contract with the
new lot address. This new smart contract is considered
the original smart contract of a new drug and contains all
the information about the lot. Manufacturers also upload
images of the produced package to IPFS.
• Drug Distributors: These include pharmacies, hospi-
tals, healthcare centers, and wholesalers that receive
drugs and present them for sale. Drug Distributors are
the original drug sellers before patients return it. They
update the relevant lot smart contract when selling a drug
package to a customer.
• Patients/Customers: The customers that approach the
pharmacies and hospitals to purchase drugs are a key ele-
ment in our system as they are the source of the unused
medicine that is returned. These customers are recorded
when purchasing medicine and also upon returning
that medicine and are identified by a unique address.
It is noteworthy that patients do not need to have an
Ethereum Address as they are not Ethereum clients and
do not interact with the smart contracts.
• Certification Agencies: These are government-
entrusted entities assigned to validate and authorize the
redistribution of resellable, returned drugs. To approve
the resale of drugs, these agencies can check for broken
seals, expiry dates, storage conditions, and perform the
necessary tests to ensure the viability of the drugs for
usage. Any medication that is suspected to be tampered
with and/or unfit for usage is not approved.
• Resellers: They are members approved by the FDA
to receive certified drugs for resale and redistribution.
Resellers can sell these drugs at a much lower price or
even donate them to specific entities as it sees fit. These
entities can participate in auctions placed by certification
agencies to acquire re-usable drug packages.
• Smart Contracts: The interaction between all those
presented entities are governed by Ethereum smart con-
tracts. Smart contracts are generated for each new lot
of drugs being produced as well as for each returned
drug package. In addition, a smart contract exists that
holds a summary of all original drugs as well as one
for returned drug packages. Only one of each drug
summary smart contracts is deployed on the blockchain;
however, original lot and returned package contracts are
dynamically by manufacturers and certification agen-
cies, respectively. The original summary contract veri-
fies manufacturers, sellers, produced drugs, and original
lot smart contract Ethereum addresses. The returned
drug summary contract keeps track of approved cer-
tification agencies and resellers as well as Ethereum
Addresses of returned packages. The original lot con-
tract, on the other hand, only handles transactions related
to that lot, and the same applies to the returned package
smart contract. Moreover, the latter also governs the
auction for selecting resellers. The last smart contract is
the reputation contract that updates resellers’ reputation
scores according to their performance.
• Decentralized Storage: The images of original drug
lots and returned drug packages have to be securely
stored. A database system cannot be used in this sys-
tem as it is inconsistent with the decentralization of the
blockchain. This poses a vulnerability in the system that
is overcome by decentralized storage. Solutions such as
IPFS and Filecoin can be used to store these images
and communicate with the blockchain in a decentralized
manner.
V. IMPLEMENTATION OF BLOCKCHAIN-BASED
SOLUTION
This section discusses the implementation details of the
aforementioned approach in addition to the application use-
case.
A. IMPLEMENTATION OF ALGORITHMS
We implement the system architecture presented in the pre-
vious section on a virtual Ethereum network for proof of
concept. The deployment utilizes the online development
environment, Remix IDE. Remix IDE supports solidity lan-
guage for smart contract testing.
Fig. 2 reflects the design of the smart contract structure
in our implementation. Smart contracts are divided into four
types: Original summary smart contract, Lot smart contract,
Returned drug summary smart contract, and returned package
smart contract. Following is a brief explanation of each of
these contracts.
1) Original summary smart contract: The rules and
regulations of the pharmaceutical supply dictate the
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FIGURE 3. Relationship between different entities of the smart contract.
entity responsible for managing various stakeholders.
Typically a governmental or federal agency, such as the
FDA, creates one summary smart contract. This con-
tract is accessed to register manufacturers and sellers
of drug lots in the original supply chain. In addition,
the drug manufactured should have been previously
approved by the FDA for production and distribution.
However, the summary contract does not hold details
of each lot after being dispatched to avoid redundancy.
2) Lot smart contract: For each drug lot, a new smart
contract is created by the manufacturer of the lot to
track the boxes within it. This type of smart contracts
represents the original drug contract before returning
by patients. The lot contract tracks the drug lot as
it moves from one owner to the next. When a drug
package is sold, the seller sends a transaction to the
corresponding lot contract to update its records.
3) Returned drug summary smart contract: When
drug packages are returned, the returned drug summary
smart contract is informed. This smart contract is
deployed once to keep track of all certification agen-
cies and approved drug resellers. It is deployed by
the same authority that created the original summary
smart contract. This smart contract can be considered
the parent contract for all re-usable drugs. When a
drug package is returned, the returned drug summary
contract is consulted to validate the certification agency
and the appointed reseller.
4) Returned drug package smart contract: For each
drug package that a patient returns, a new smart con-
tract is created to capture the details of the returned
package. This smart contract is deployed by the cer-
tification agency that approved its redistribution. The
smart contract is updated whenever the drugs from that
packaged are re-sold. This smart contract also handles
selecting returned drug resellers.
5) Reputation smart contract: This is a separate smart
contract that manages the reputation score for approved
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FIGURE 4. Interactions showing the function calls for purchase, returning and resale of drugs.
resellers to ensure honesty and quality of service. The
reputation smart contract, like the summary contracts,
is the responsibility of the agency that overlooks the
supply chain.
Fig. 3 shows the various smart contracts that interact
together and how they are related to each other. When a
new lot of drugs is created by a manufacturer for the first
time, it creates a new instance of the lot contract for it. All
operations related to that batch of drugs go through the lot
contract. This lot is identified by a unique Ethereum address
given to the smart contract. This address is linked to data the
drug name, its current owner, price of each box, the number
of drug boxes it contains, manufacturing, and expiry date.
In addition, this smart contract keeps track of all sold boxes.
The addresses of all lot smart contracts are recorded in the
original summary contract. Moreover, the returned package
smart contract is created upon returning a drug from any lot.
Multiple drugs can be re-sold from the same lot and given
different Ethereum addresses. When the drugs are admitted
for resale, it is given a new price and new seller based on
an auction-based selection algorithm. This smart contract
contains this information, as well as the address of the original
lot and the address of the certification agency that approved
it. Besides creating this contract, the returned drug summary
contract is also updated. This summary smart contract keeps
track of all approved certification agencies, resellers, and
returned packages in one place. All returned packages need
to be added to this summary contract. To establish trust in
resellers, patients provide their feedback on the interaction
with the reseller, both positive and negative. This directly
affects a reputation score that is managed by the reputation
smart contract. This contract modifies the reputation score of
resellers according to their behavior.
Fig. 4 presents the interactions between smart contracts
and different entities on the blockchain that lead to adding,
selling, retaking, validating, and re-selling drugs. The man-
ufacturer is the owner of the original lot contract, and it
is responsible for creating a new instance for each new lot
produced and requesting approval for dispatching the lot
from the original summary smart contract. This summary
contract validates the drug being produced and the manufac-
turer creating the lot smart contract. Manufacturers also add
images of the original lot to the decentralized storage system.
Once the lot has been dispatched, the ownership changes
through the supply chain until it reaches the final drug sellers.
When a pharmacy or a hospital sells a drug box to a patient,
it updates the relevant lot smart contract. After the purchase,
the patient can return the drug to a certification agency off-
chain. Once an authorized agency approves the medicine, the
drug is admitted, and the agency adds that drug package to
the returned drug summary contract. This contract validates
the agency, the reseller, and the package data. Then, a returned
drug package contract is created, and an image of the returned
package is uploaded to the storage system by the certified
agency. The drug is then transferred to the approved reseller
for redistribution. Whenever the reseller sells a drug box,
it updates the drug package contract.
Fig. 5 presents the sequence of messages that lead to select
an appropriate reseller and validate its integrity. It starts with
the commencement of an auction by the certification agency.
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FIGURE 5. Interactions showing the process of choosing a reseller and
updating reputation score.
The auction has specific parameters set, such as the price
to start bidding at and the minimum required reputation for
resellers to bid. The auction is announced via an event that
is triggered by the returned package smart contract. Resellers
that are interested in acquiring the drug place increasing bids
and transfer deposits to ensure their commitment. The certi-
fication agency then closes the auction, and the last bidder
gets the drug package. When the drug gets sold eventually,
the patient can provide its feedback to a reputation smart
contract. This contract records the feedback and computes
the new reputation score internally, as explained earlier in the
Implementation section. Then, the reputation score is updated
and announced to all entities.
The tracking of drugs in our solution consists of two main
parts: the original drug supply and the returned drug valida-
tion. The pseudocodes for these two processes are represented
in algorithms 1 and 2, respectively. These algorithms provide
a brief explanation of the smart contract code at a higher
level as opposed to the aforementioned Solidity code. The
first algorithm starts with the production of every drug lot.
The manufacturer of this lot deploys an original lot contract,
uploads the drug lot image to the decentralized storage sys-
tem. The ownership of the drug lot then changes from the
manufacturer to the next entity as the drug lot moves through
the supply chain and is claimed by different members until it
reaches a retailer. Hospitals and pharmacies that sell the drug
boxes to end users update the relevant smart contract after
each transaction.
Similarly, algorithm 2 represents the process of returning
a drug package by a customer. The same logic applies when
donating drugs by a customer, a retailer, or even a wholesale
distributor. The drugs are supplied to a certification agency
that informs the summary contract and creates a new returned
package smart contract. This agency provides the package
to a reseller that updates said smart contract whenever a
customer purchases a returned drug.
Algorithm 1 Dispatching of Original Drug Lots
Input: drug data, drug code, lot address
1 Modifier: onlyManufacturer
2 Send drug data to the original drug summary contract.
3 if drug code is valid ∧ manufacturer is approved then
4 Authorize dispatching of Drug lot and commit to the
original summary contract.
5 Create the original drug lot contract on the
blockchain.
6 Manufacturer uploads the drug lot image to the
decentralized storage system.
7 Change ownership of lot until the acquisition by a
seller via the lot smart contract.
8 Sell Drugs to patients using the smart contract.




Algorithm 2 Returning and Resale of Drug Package
Input: drug data, reseller address
1 Modifier: onlyCertificationAgency
2 if drug is approved by CA then
3 Send drug data to the summary contract.
4 if CA address is verified ∧ reseller address is
verified then
5 Add Returned Drug Package to the summary
contract.
6 Create a returned package contract.
7 Upload repackaged drug image to the
decentralized storage system.
8 Choose a reseller to receive the package
9 Transfer re-usable package to the selected
reseller.
10 Selling Drugs.







The process of choosing a reseller is done using an auction
mechanism. The returned summary contract has a list of
approved resellers that are allowed to sell re-consumable
drugs. Once a drug is returned, and a certification agency
approves it, it starts an auction that allows the resellers to
possess this resellable package and sell it as shown in algo-
rithm 3. It starts by opening the auction and announcing to all
resellers that it is open for bidding. The resellers compete by
offering an increasing price that they believe that they would
still gain profit from selling. The certification agency could
also put an upper price cap on the price for the interest of the
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FIGURE 6. Utilizing the DApp of the blockchain-based solution to purchase reusable drugs.
customers. When a bidder offers a price, they transfer that
amount to the returned package smart contract that is being
auctioned as a deposit to ensure their commitment. After
every new bid, the available deposit is returned to the previous
bidder before accepting the new bid. The auction continues
until the closing time. Upon auction closure, the winning bid-
der is announced, and the drug package is assigned to them.
The available balance in the returned package smart contract
belongs to the winning bidder. Therefore, that amount is
transferred back to the corresponding reseller.
When certification agencies start an auction, they
announce a starting price, a closing time, as well as a
minimum reputation score, as shown in algorithm 4. Any
reseller that wants to place a bid should satisfy the reputation
requirements. After an interaction, a patient can inform the
smart contract if a transaction was satisfactory or inadequate.
Equations 1 and 2 below describe how the reputation score
of a reseller, Rep(t) is updated after good or bad feedback by
a patient, respectively. The adjusting factor, AF , described,
is an arbitrary measure of how forgiving the smart contract is.
Changing this value results in causing the reward to become
more generous or the punishment more severe. The constant
values presented in addition to AF were designed to scale
the reputation value up or down depending on the feedback.
AF is recommended to be given a value of 2 or more. In our
implementation, we give AF a value of 4, where we consider
the raters to be trusted and would give an honest response.






Rep(t) = Rep(t − 1)−
Rep(t − 1) ∗ 0.95
4 ∗ (10− AF)
(2)
B. DECENTRALIZED APPLICATION
This section presents the process of utilizing the DApp by
patients to purchase re-consumable drugs from approved
resellers. The returned drug package is linked to a smart
contract that contains all of its metadata, methods, and events.
Any modification to the drug package is logged in this smart
contract, which is identified by its unique Ethereum address.
This address is translated to a QR code that is printed on
the drug boxes for easier, more efficient transactions. Fig. 6
explains how to use DApps to sell drugs to patients. Initially,
the QR code would be stamped on the drug box. Resellers
scan them to get the Ethereum address of the relevant smart
contract to contact in addition to the number of this box. The
DApp uses the web3.js library to reach an Ethereum gateway
such as Infura. This is an Ethereum client that communicates
with the Ethereum blockchain on behalf of the user. Ethereum
gateways such as Infura enable users to access the blockchain
without being obliged to locally install full Ethereum nodes.
Due to resource requirements of establishing a full Ethereum
node, gateways such as Infura provide a light-weight solu-
tion for users to interact with the blockchain. Moreover,
Infura supports libraries that are vital to communicate with
Ethereum, such as the Web3.js API suite
Having the address of the smart contract, the gateway
provides access to all of its methods and events. Therefore,
the status of the smart contract can be modified, assuming it
satisfies the access policy of the smart contract. In addition,
the Ethereum gateway can access all the events emitted by
the smart contract. The gateway then can update the user
about any requested information. Accessing the information
through an Ethereum client ensures the integrity of the data as
it is stored in an immutable and permanent ledger. Moreover,
the authenticity of the drug can be ensured by tracking the
trail of events of ownership change from the Certification
Agency. For even more verification, the original lot Ethereum
address is included in the returned package smart contract.
The history of the original ownership of the drug can be
tracked using said address. This process is done without
the interference of the user to automatically access smart
contracts for sale and drug verification.
VI. TESTING AND VALIDATION
This section discusses the validation of the expected outcome
for the implemented approach. The code for the solution
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Algorithm 3 Selecting Reseller by Bidding
Input: closing time, start price, minimum reputation
1 Modifier: onlyReseller
2 if Auction open already then
3 Set auction parameters.
4 Set auction status as open.





/* Bidding starts by resellers. */
9 if The reseller is approved ∧ reseller meets the minimum
reputation requirements ∧ auction is open then
10 Check the price offered by the reseller.
11 if price is higher than the previous bidder ∧ the
amount of ethers transferred is sufficient then
12 if it is not the first bidder then
13 Transfer back deposit to the previous bidder.
14 Change deposit of the previous bidder to
zero.
15 end
16 Change the address of the highest bidder.







/* Certification Agency requests
auction closure */
24 if auction is open ∧ closing time has passed ∧ at least
one bid has been placed then
25 Change the auction status to closed.
26 Return deposit to the reseller.
27 Announce the closing of the auction.
28 else
29 Keep auction open.
30 end
was implemented, deployed, and tested on Ethereum using
Remix IDE. Remix provides a test Ethereum network for
deploying and testing smart contracts. Remix also has various
plugins that support the debugging of the deployed code, per-
forming unit testing, and conducting a sufficient performance
analysis on the code. A log is generated and displayed for
each transaction to simulate a real Ethereum network. These
logs can be used to explore transactions as they include the
inputs, outputs, events triggered, as well as the execution and
transaction gas cost of the transaction. In addition, errors and
exceptions are also displayed in these logs. Errors include
exceeding the gas cost limit, run time errors, and restrictions
enforced by the smart contract itself. Such constraints are
required to maintain a level of privacy in the system. As such,
some methods are restricted to only specific members.
Algorithm 4 Updating Reputation of Resellers
Input: reseller address, transaction status
Output: updated reputation score
1 if reseller is approved ∧ patient has not provided
feedback about this reseller then
2 Record feedback. if transaction was satisfactory
then
3 Reseller is rewarded by increasing its reputation
score, as shown in equation 1.
4 else
5 Reseller is punished by decreasing its reputation






FIGURE 7. Event showing a new drug lot being dispatched.
To evaluate the functionality of our smart contracts,
we deployed both the original drug supply summary smart
contract at 0xc5a98F66719ee680272d8289B8CE227174E2
CDDc and the returned drug summary smart contract at
the address 0× 48ebDb0D8107D12E58266EC9efdc82b047
f59FFA. The addresses of both of these contracts are static
and were embedded in all lot smart contracts and returned
package smart contracts. In addition, we simulated a com-
plete supply chain process by creating a couple of lot smart
contracts with a certain quantity of approved drugs. These
contracts are identified by an Ethereum address and include
information about the drug lot. The drug lot was approved by
the original drug summary contract to have a valid drug type
and is produced by a legitimate manufacturer. The lot was
dispatched, and it was claimed by different entities ending
with a retailer. These changes were observed through the pre-
viously mentioned logs. Fig. 7 shows an event being triggered
announcing a new drug lot is produced. It is worth noting that
the address that triggered the event denoted in the first field
of the event is the same as the first argument in the args array,
lotAddress, which is the address of the smart contract itself.
After selling some drug boxes to consumers, a part of
it was returned for re-selling. Fig. 8 shows all the data of
the re-usable drug along with the address of the smart con-
tract after it has been approved. It includes the drug name,
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FIGURE 8. Information about the returned drug package with original lot
address.
manufacturing, and expiry date, the address of the current
owner of the drug, the price (donated for free in this case),
the number of boxes that were returned, and the address of
the reseller that was selected. Most importantly, this type of
smart contract contains the address of the original lot that
these packages belonged to. This is vital for checking the
history of these specific boxes, including the manufacturer,
retailer, the original price, and the entire chain of ownership.
If the smart contract at that specific address does not exist,
the return is rejected as it is considered inauthentic.
After the purchase was made, a customer can return that
medicine if it has not been opened, used, and has been stored
in appropriate conditions. The certification agency performs
the appropriate testing off-chain to approve or reject the
drug. Assuming the return price is significantly lower as per
the guidelines of the officials, the customer can attempt to
return that drug for other patients to benefit from. Once the
certification agency has approved the drug and added it to
the returned summary contract, it creates a new contract for
the returned package and broadcast an event to announce the
FIGURE 9. Event showing availability of new resellable drug.
FIGURE 10. Event showing the resale of a returned drug package.
availability of a new re-consumable drug and shown in fig. 9.
The agency assigns a new seller for the drug, as seen in the
event being broadcasted.
After the new returned drug package smart contract has
been created, the reseller can now sell or donate the drug
to other patients. Fig. 10 shows an event triggered when a
patient purchases one of the drug boxes out of a resellable
drug package from a drug reseller. The event states the box
number as well as the drug package address that corresponds
to the smart contract Ethereum address. Alternatively, the
smart contract could reject the sale in case of any errors, such
as the expiry of the returned drug, as shown in fig. 11.
VII. EVALUATION AND ANALYSIS
This section presents a cost analysis of the developed solution
and discusses the security aspect of the system. In addition,
the generalization of the system is discussed in addition to
a comparative analysis with other solutions as well as the
challenges faced by such an approach.
A. COST ANALYSIS
Each function call in the smart contract code requires some
gas to execute. Gas is a standardized unit to measure the
cost of computer operation execution of a transaction in an
Ethereum smart contract. Each operation executed costs a
specific amount of gas. The cost for all the operations in
a function is referred to as the execution gas. The actual
gas cost for the transaction, called the transaction gas, also
includes the cost of sending the transaction to the blockchain.
The methods in the smart contract are executed on a virtual
Ethereum network on Remix IDE. This development environ-
ment offers an approximation of the cost incurred from each
transaction. The cost depends on multiple factors, including
the input parameters, code size, the complexity of the code,
and the gas cost requested by the sender [17]. Table 1 shows
all function calls in the smart contracts along with the exe-
cution cost in gas approximated by Remix. Also, the cost in
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TABLE 1. Gas cost of Ethereum functions in USD.
FIGURE 11. Error message showing that the drug cannot be re-sold as it
has expired.
USD is presented for easier interpretation. While there is no
standard conversion between gas and a fiat currency such as
the US dollar, the transaction executor chooses the rate of
conversion depending on his preference. Transactions on the
Ethereum are executed by miners in the network. Miners val-
idate the transactions and form them into blocks and append
them to the blockchain, for which they are rewarded with two
ethers. In addition, for each transaction, the sender adds a
reward to incentivize the miners to pick their transaction from
the transaction pool. This is denoted by the gas price set by
the sender. Higher gas price results in a higher probability
for the transaction to be mined and added to a block to be
deployed on the blockchain. The cost analysis includes three
rates of conversion corresponding to slow, average, and fast
execution of the transaction, and we are going to use the
average gas price suggested by ETH Gas Station as of April
12th, 2020 [18].The slow or cheap execution requires 0.9
Gwei per gas, while the average execution costs 1.1 Gwei per
gas, and fast execution costs 1.6 Gwei per gas. The costs for
creating the two smart contracts are the highest, as can be
seen in the table. This is due to deploying and running the
contracts on the Ethereum blockchain, in addition to calling
the constructor. The full smart contract code is much bigger
in volume than a typical function call, and so is the cost of
its execution. Nevertheless, similar to normal method calls,
the cost of deploying the smart contract is contingent on the
size of the contract, the number of parameters passed to the
constructor, the complexity of this constructor, along with
an extra cost incurred for sending the smart contract to the
blockchain. It is to be noted that at the time of writing this
article, 1 Ether equals 163.67 USD. The cost of all methods
is $0.09 or lower for each method for slow execution, $0.1 or
lower for average execution, and $0.15 or lower for fast exe-
cution. This proves the feasibility of utilizing smart contracts
for tracking re-consumable drugs.
B. SECURITY ANALYSIS
In this subsection, an analysis of the system’s security will
be presented. Our proposed solution is built on the Ethereum
blockchain. The blockchain technology offers invaluable
security advantages and features for the system. Some sig-
nificant security features related to our solution are discussed
below:
• Authorization and Accountability: The pharmaceuti-
cal supply chain is complex with a large number of
contributors, including suppliers, sellers, buyers, and
many more. Losing track of the status of the medicine
andmiscalculation becomes highly possible, with a large
number of drugs moved around. On the blockchain,
all transactions are permanent and cannot be modified,
which means that all activity is recorded, and each
member is held accountable for their actions. In addi-
tion, we have implemented modifiers that allow certain
authorized members to access specific methods. Each
member is given limited capability based on its prede-
fined role. For instance, only certification agencies are
allowed to add returned drug packages to the returned
drug summary smart contract.
• Availability: The stakeholders in the system or anyone
that requires access to the smart contracts are always
guaranteed that the smart contract will be responsive at
all times. This assumption is valid due to the decentral-
ized nature of the blockchain. The same smart contract
is available on thousands of mining nodes at the same
time. Therefore, if some of those nodes are unavailable
for any reason or are overwhelmed with transactions,
a number of others will be available for confirmation
of any transaction within the 20 seconds block time of
the Ethereum blockchain. This results in extremely slim
chances of the data being compromised due to a DDoS
attack against our system. All data is stored securely
in an immutable tamper-proof decentralized ledger that
eliminates the single point of failure.
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• Non-repudiation: All transactions performed on the
blockchain are secured by a digital signature from the
message sender. Therefore, no member can deny buy-
ing, selling, approving, or disapproving drugs on the
blockchain. All logs are maintained in the ledger and
are permanent and protected from being tampered with.
This maintains the accountability of each member for
all of their actions. All activities are traceable back to
its source, which is recorded in a permanent ledger.
This forces entities to follow all the policies by updat-
ing the ledger, performing the appropriate testing on
returned drugs, and ensuring the process is transparent
and authentic.
In addition to these security features, there is a need to
ensure that the proposed system is robust as it will be publicly
available. Therefore, it could be a target for some attacks such
as:
• DDoS Attacks: A Denial-of-Service (DoS) attack is
a cyber-attack where an attacker attempts to force a
system to be unavailable by intentionally overwhelming
it with a large number of packets. A Distributed-Denial-
of-Service (DDoS) attack is a special case of DoS where
the incoming packets are from multiple sources. These
devices may be colluding together or were compromised
by the attacker. The blockchain technology is resilient to
such attacks to a great extent. The decentralized nature
of the blockchain enables it to run even if several nodes
were compromised.
• The Majority attack: Miners join the Ethereum net-
works to mine blocks by grouping transactions, validat-
ing them, and forming blocks to append it to the global
blockchain and update the world state. Due to the use of
the Proof-of-Work (PoW) consensus protocol, a miner’s
chance of adding his block is associated with his hashing
power. Therefore, a single miner or a small group of
miners cannot gain control over the entire network [19],
[20]. However, if a group of miners was able to control
over half of the entire hash rate of the Ethereum network,
they can control the network. This is known as the
majority attack or the 51% attack [19]. Additionally,
transaction malleability targets disrupting the state of
a blockchain by introducing malicious transactions that
are semantically similar to benign transactions [21].
• The DAO attack: This type of attack compromises a
blockchain-specific vulnerability inspired by the attack
on the DAO in 2016 [22]. This incident was caused as
the blockchain was susceptible to ‘‘call to unknown;;
and ‘‘reentrancy’’; hence, this attack is also known as
the reentrancy attack. This vulnerability was mitigated
by a hard fork in the blockchain that fixed those bugs.
C. GENERALIZATION
Our proposed solution is designed to be generic enough for
most supply chain applications. Nonetheless, the implemen-
tation that uses Ethereum blockchain smart contracts should
be public as all members can view the smart contract as well
TABLE 2. Comparison with state-of-the-art.
as events broadcasted by the smart contract. Although some
methods are only accessed by authorized members, the state
of the smart contracts is publicly visible for all members of
the Ethereum blockchain. Our solution supports applications
that require the transfer of goods between entities with limited
accessibility for each member. In addition, some approvals
might need to be collected for certain operations. With min-
imal adjustments, the source code for the smart contracts
described in this article, our solution can be implemented in
numerous use cases similar to pharmaceutical supply chains.
D. QUALITATIVE COMPARISON
The comparative analysis, in contrast with the latest solutions
described in Table 2, shows that our proposed approach offers
a solution to track and approve re-usable drugs as they are
returned from original owners. Existing solutions suffer from
drawbacks such as centralization [11], private implementa-
tions [13], or lack of smart contract support [12], [14]. On the
other hand, our solution proposes a decentralized solution
to track drugs from the original manufacturer as well as the
return of unused drugs. This approach utilizes the Ethereum
blockchain smart contracts to implement a publicly available
system. However, the decentralized front-end application for
users to utilize our solution requires some improvement. This
is one of the future goals that we are looking to implement in
future development.
E. CHALLENGES
Blockchain had a significant impact on the healthcare indus-
try. It is showing incredible potential in applications such as
the pharmaceutical supply chain. In this section, we present
major challenges facing our blockchain-based approach.
• Smart contracts: Programming blockchain smart con-
tracts introduce some constraints on the system as com-
pared to classic centralized servers [23]. Smart contract
developers face challenges such as the high standard
for security by the blockchain, limited debugging, and
Solidity restrictions. In addition, smart contract code
needs to be highly efficient by storing only vital informa-
tion andminimizing operations. The cost of execution of
Ethereum functions depends mainly on the complexity
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of the method. Therefore, optimizing algorithms is cru-
cial to reduce gas consumption as much as possible.
• Scalability: There is a limit on the throughput of any
system implemented using blockchain networks. For
instance, Ethereum blockchain offers about 15 trans-
actions per second [24], [25]. This poses a cap on the
number of transactions in the proposed approach. As the
input flow increases, it is not reflected in the output flow
due to this limitation. A scalable service provider should
be able to allocate more resources whenever need. How-
ever, this is not possible in such systems implemented on
the blockchain.
• Time delay: Nodes in the blockchain consume a lot of
time and power to group transactions, validate them,
store them, form a block, and finally broadcast their
results to other nodes [26]. This is done for each node
until all miners on the network reach consensus and
agree on a block to append. The Ethereum blockchain
adjusts the difficulty for the consensus protocol to take
about 20 seconds. This time period gives the nodes
enough time for processing and communicating with
other nodes. In addition to the time for block formation,
some time is allocated for the block to be confirmed.
The block is considered to be confirmed if it is fol-
lowed by a specific number of blocks such that no
other parallel side chains would overwrite the current
chain of blocks. When a total of 10 blocks formed
in front of some block, also called ten confirmations,
that transactions in that block are considered to be irre-
versible and permanent. In Ethereum, this would take
approximately 3minutes per block. However, if multiple
transactions from different sources in our system were
included in the same block, they would be confirmed
at the same time. In addition, low gas prices offered by
users of the blockchain introduce additional delay, as it
lowers the probability that miners would include their
transaction in the upcoming block.
• Privacy concerns: The public availability of the
source code introduces a privacy compromise, although
blockchain still maintains the anonymity of all of
its members. Most blockchain networks, including
Ethereum, do not enforce policies to protect the data
privacy [27]. All transactions are distributed across the
entire network. Somemeasures were taken to ensure that
only authorized entities can trigger certain methods in
smart contracts. However, all information is still publicly
available for anyone to view. Knowing such information
is an invasion of privacy and can be exploited to harm
the stakeholders involved.
VIII. CONCLUSION
In this article, we have presented a blockchain-based solution
to track the origin of returned, reconsumable drugs from its
manufacturing until they are re-sold to customers. This pro-
cess involves interaction from many different members that
are all governed by the smart contracts. The smart contract
code deployed on Ethereum has been made available as a
Github repository. We used Remix development environment
to deploy our solution, test and validate its functionality
and outcome, and perform important analyses. All func-
tionalities of the smart contract are shown to produce the
expected outcome as per the problem description. Accord-
ing to the cost analysis presented, the estimated execution
gas for the methods involved was shown to be minimal.
Given the mentioned Ether rate at the time of this writing,
all methods require $0.1 or less to execute for an average
gas price. This low cost proves the feasibility of deploy-
ing such a system to be used for drug tracking and resale.
Moreover, our security analysis discussed the resilience of
smart contract code against major security vulnerabilities and
attacks. Our solution can also be altered to be applicable
to other use cases, as described. Finally, we presented a
qualitative comparison against some of the similar solutions
in addition to the major challenges that face our blockchain-
based approach. As future work, we are in the process of
developing an end-to-end solution with back-end and front-
end DApps to be implemented on the Ethereum mainnet.
The mentioned smart contracts present the back-end of the
system, while the front-end is similar to web applications,
where it focuses on the user interface and the overall user
experience.
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